Justine V Cohen1, Elizabeth I Buchbinder2. 1. Pennsylvania Hospital, University of Pennsylvania Abramson Cancer Center, 230 W. Washington Square, Philadelphia, PA, 19106, USA. justine.cohen@pennmedicine.upenn.edu. 2. Dana Farber Cancer Institute, Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: The past decade has been a time of remarkable advancement in the field of adjuvant therapy for patients with resected high-risk melanoma. Here, we review the data for adjuvant melanoma and raise questions about the best choice of therapy for an individual patient. RECENT FINDINGS: There have been several new adjuvant approvals including immunotherapy and targeted therapy approaches. Nivolumab is approved for patients with nodal involvement or metastatic disease after resection. Pembrolizumab is approved for patients with nodal involvement after resection. In addition, the combination of dabrafenib and trametinib is approved in patients' nodal involvement after resection whose tumors harbor BRAFV600E/K mutations. New therapeutic opportunities have provided promising options for patients with high-risk disease. These advances have significantly challenged the previous standard-of-care for this population of patients. Data is still forthcoming regarding durability of benefit and safety of these new treatments.
PURPOSE OF REVIEW: The past decade has been a time of remarkable advancement in the field of adjuvant therapy for patients with resected high-risk melanoma. Here, we review the data for adjuvant melanoma and raise questions about the best choice of therapy for an individual patient. RECENT FINDINGS: There have been several new adjuvant approvals including immunotherapy and targeted therapy approaches. Nivolumab is approved for patients with nodal involvement or metastatic disease after resection. Pembrolizumab is approved for patients with nodal involvement after resection. In addition, the combination of dabrafenib and trametinib is approved in patients' nodal involvement after resection whose tumors harbor BRAFV600E/K mutations. New therapeutic opportunities have provided promising options for patients with high-risk disease. These advances have significantly challenged the previous standard-of-care for this population of patients. Data is still forthcoming regarding durability of benefit and safety of these new treatments.
Authors: Daniel G Coit; Robert Andtbacka; Christopher J Anker; Christopher K Bichakjian; William E Carson; Adil Daud; Raza A Dilawari; Dominick Dimaio; Valerie Guild; Allan C Halpern; F Stephen Hodi; Mark C Kelley; Nikhil I Khushalani; Ragini R Kudchadkar; Julie R Lange; Anne Lind; Mary C Martini; Anthony J Olszanski; Scott K Pruitt; Merrick I Ross; Susan M Swetter; Kenneth K Tanabe; John A Thompson; Vijay Trisal; Marshall M Urist Journal: J Natl Compr Canc Netw Date: 2012-03 Impact factor: 11.908
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo Antonio Ascierto; Jon M Richards; Celeste Lebbe; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Fareeda Hosein; Veerle de Pril; Michal Kicinski; Stefan Suciu; Alessandro Testori Journal: Eur J Cancer Date: 2019-08-07 Impact factor: 9.162
Authors: Jeremy L Davis; Russell C Langan; Katherine S Panageas; Junting Zheng; Michael A Postow; Mary S Brady; Charlotte Ariyan; Daniel G Coit Journal: Ann Surg Oncol Date: 2017-03-16 Impact factor: 5.344
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: N Jacquelot; M P Roberti; D P Enot; S Rusakiewicz; N Ternès; S Jegou; D M Woods; A L Sodré; M Hansen; Y Meirow; M Sade-Feldman; A Burra; S S Kwek; C Flament; M Messaoudene; C P M Duong; L Chen; B S Kwon; A C Anderson; V K Kuchroo; B Weide; F Aubin; C Borg; S Dalle; O Beatrix; M Ayyoub; B Balme; G Tomasic; A M Di Giacomo; M Maio; D Schadendorf; I Melero; B Dréno; A Khammari; R Dummer; M Levesque; Y Koguchi; L Fong; M Lotem; M Baniyash; H Schmidt; I M Svane; G Kroemer; A Marabelle; S Michiels; A Cavalcanti; M J Smyth; J S Weber; A M Eggermont; L Zitvogel Journal: Nat Commun Date: 2017-09-19 Impact factor: 14.919
Authors: Pippa G Corrie; Andrea Marshall; Janet A Dunn; Mark R Middleton; Paul D Nathan; Martin Gore; Neville Davidson; Steve Nicholson; Charles G Kelly; Maria Marples; Sarah J Danson; Ernest Marshall; Stephen J Houston; Ruth E Board; Ashita M Waterston; Jenny P Nobes; Mark Harries; Satish Kumar; Gemma Young; Paul Lorigan Journal: Lancet Oncol Date: 2014-04-15 Impact factor: 41.316
Authors: R J Lee; G Gremel; A Marshall; K A Myers; N Fisher; J A Dunn; N Dhomen; P G Corrie; M R Middleton; P Lorigan; R Marais Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Axel Hauschild; Reinhard Dummer; Dirk Schadendorf; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Thierry Lesimple; Ruth Plummer; Kohinoor Dasgupta; Tomas Haas; Mark Shilkrut; Eduard Gasal; Richard Kefford; John M Kirkwood; Georgina V Long Journal: J Clin Oncol Date: 2018-10-22 Impact factor: 44.544
Authors: Harriet M Kluger; David A Hafler; Liliana E Lucca; Pierre-Paul Axisa; Benjamin Lu; Brian Harnett; Shlomit Jessel; Le Zhang; Khadir Raddassi; Lin Zhang; Kelly Olino; James Clune; Meromit Singer Journal: J Exp Med Date: 2021-04-05 Impact factor: 14.307